These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 34115146)
21. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival. Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532 [TBL] [Abstract][Full Text] [Related]
22. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images. Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242 [TBL] [Abstract][Full Text] [Related]
23. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348 [TBL] [Abstract][Full Text] [Related]
24. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
25. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models. Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427 [TBL] [Abstract][Full Text] [Related]
26. Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status. Park CJ; Choi YS; Park YW; Ahn SS; Kang SG; Chang JH; Kim SH; Lee SK Neuroradiology; 2020 Mar; 62(3):319-326. PubMed ID: 31820065 [TBL] [Abstract][Full Text] [Related]
28. Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471 [TBL] [Abstract][Full Text] [Related]
29. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes. Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676 [TBL] [Abstract][Full Text] [Related]
30. Machine learning: a useful radiological adjunct in determination of a newly diagnosed glioma's grade and IDH status. De Looze C; Beausang A; Cryan J; Loftus T; Buckley PG; Farrell M; Looby S; Reilly R; Brett F; Kearney H J Neurooncol; 2018 Sep; 139(2):491-499. PubMed ID: 29770897 [TBL] [Abstract][Full Text] [Related]
31. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI. Zhang X; Tian Q; Wang L; Liu Y; Li B; Liang Z; Gao P; Zheng K; Zhao B; Lu H J Magn Reson Imaging; 2018 Oct; 48(4):916-926. PubMed ID: 29394005 [TBL] [Abstract][Full Text] [Related]
32. Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade. Doig D; Kachramanoglou C; Dumba M; Tona F; Gontsarova A; Limbäck C; Jan W Clin Radiol; 2021 Oct; 76(10):785.e9-785.e16. PubMed ID: 34289936 [TBL] [Abstract][Full Text] [Related]
33. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas. Yang X; Lin Y; Xing Z; She D; Su Y; Cao D Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488 [TBL] [Abstract][Full Text] [Related]
34. Simplified perfusion fraction from diffusion-weighted imaging in preoperative prediction of IDH1 mutation in WHO grade II-III gliomas: comparison with dynamic contrast-enhanced and intravoxel incoherent motion MRI. Wang X; Cao M; Chen H; Ge J; Suo S; Zhou Y Radiol Oncol; 2020 Jun; 54(3):301-310. PubMed ID: 32559177 [TBL] [Abstract][Full Text] [Related]
35. MR textural analysis on T Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606 [TBL] [Abstract][Full Text] [Related]
36. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387 [TBL] [Abstract][Full Text] [Related]
37. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network. Choi KS; Choi SH; Jeong B Neuro Oncol; 2019 Sep; 21(9):1197-1209. PubMed ID: 31127834 [TBL] [Abstract][Full Text] [Related]
38. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115 [TBL] [Abstract][Full Text] [Related]
39. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. Joo B; Han K; Ahn SS; Choi YS; Chang JH; Kang SG; Kim SH; Zhou J; Lee SK Eur Radiol; 2019 Dec; 29(12):6643-6652. PubMed ID: 31175415 [TBL] [Abstract][Full Text] [Related]
40. Quantitative texture analysis in the prediction of IDH status in low-grade gliomas. Jakola AS; Zhang YH; Skjulsvik AJ; Solheim O; Bø HK; Berntsen EM; Reinertsen I; Gulati S; Förander P; Brismar TB Clin Neurol Neurosurg; 2018 Jan; 164():114-120. PubMed ID: 29220731 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]